Abstract:N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), group 2A carcinogens, were detected in finished drug products, including metformin, ranitidine, sartans and other drugs which caused multiple recalls in the USA and Europe. Important studies also reported the formation of NDMA when ranitidine and nitrite were added to simulated gastric fluid. Our objective was to screen finished drug products from Europe and USA for nitrosamine impurities and investigate the formation of NDMA in metformin finished drug products when added to simulated gastric fluid. One dosage unit of 30 different commercially available drugs, including metformin, sartans, and ranitidine were tested for NDMA, NDEA, and dimethylformamide (DMF) impurities, using a liquid chromatography-mass spectrometry (LC-MS) method. Then, 6 metformin finished drug products were tested in stomach conditions for 2 h at 37 °C in a 100 mL solution with a pH of 2.5 and different nitrite concentrations (40, 10, 1, 0.1 mM) and tested for NDMA, and DMF using LC-MS. We measured NDMA, NDEA, and DMF in 30 finished drug products. NDMA and DMF were quantified for metformin drug products in simulated gastric fluid with different nitrite concentrations. None of the 30 drugs showed concerning levels of NDMA, NDEA, or DMF when tested as single tablets. However, when metformin tablets are added to simulated gastric fluid solutions with high nitrite concentrations (40 mM and 10 mM), NDMA can reach amounts of thousands of nanograms per tablet. At the closest concentration to physiologic conditions we used, 1 mM, NDMA is still present in the hundreds of nanograms in some metformin products. In this in vitro study, nitrite concentration had a very important effect on NDMA quantification in metformin tablets added to simulated gastric fluid. 1 mM nitrite caused an increase above the acceptable daily intake set by the U.S. Food and Drug Administration (FDA) for some of the metformin drugs. 10 mM, 40 mM nitrite solutions generated NDMA amounts exceeding by more than a hundred times the acceptable daily intake set by the FDA of 96 nanograms. These findings suggest that metformin can react with nitrite in gastric-like conditions and generate NDMA. Thus, patients taking metformin could be exposed to NDMA when high nitrite levels are present in their stomach, and we recommend including a statement within the Patient Package Inserts/Instructions for use.

Permitted daily exposure limits for noteworthy N‐nitrosamines

Risk characterization of N- nitrosodimethylamine in pharmaceuticals

Occurrence of <i>N</i>-Nitrosamines as Harmful Impurities in Pharmaceuticals

DETERMINATION OF N-NITROSODIMETHYL AMINE (NDMA) AND N-NITROSODIETHYL AMINE (NDEA) IN MEDICINES CONTAINING SARTAN AND ITS DERIVATIVES

Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications

N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP

Nitrosamines, ICH Q3A-Q3E, Global Substance Registration System (GSRS), N-nitroso dimethyl amine (NDMA), Drug substance life cycle.

THE MEDICAL IMPACT OF EMERGENT BANNING OF N-NITROSODIMETHYLAMINE (NDMA)- CONTAMINATED ANTIHYPERTENSIVE DRUG: A NATIONWIDE LONGITUDINAL COHORT STUDY

N-Nitrosodimethylamine investigations in MutaTMMouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations

Nitrosamine carcinogenesis in 5120 rodents: chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting (3, 6 or 20 weeks) and of species (rats, mice or hamsters)

Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients

Oncogenicity tests of p-nitroso-N,N-dimethylaniline and p-nitroso-N,N-diethylaniline in NZR rats and NZO mice

Elevated Urinary Levels of Carcinogenic N-Nitrosamines in Patients with Urinary Tract Infections Measured by Isotope Dilution Online Spe Lc-Ms/Ms

Highly Sensitive and Robust LC-MS/MS Method for Determination up to 15 Small Molecule Nitrosamine Impurities in Pharmaceutical Drug Substances

Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential

[Calculation of maximum allowable concentration of N-nitrosodimethylamine and N-nitrosodiethylamine based on chronic experiments in mice]

Development of a Sensitive and Stable GC-MS/MS Method for Simultaneous Determination of Four N-nitrosamine Genotoxic Impurities in Sartan Substances

Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities

Metformin drugs under simulated gastric conditions can generate high nitrite-dependent levels of N-nitrosodimethylamine

Alternative Methods For The Analysis Of Ndma And Other Nitrosamines In Water